Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma
Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma Use of Corticosteroids Prior to Yescarta Infusion Has the Potential to Impact the BenefitRisk Profile Based on Data from a Cohort of ZUMA-1 Patients — — Response Rates Observed in New Analysis Remain Consistent with Pivotal Cohorts — Kite, a Gilead Company today announced findings from a new analysis of the ZUMA-1 trial of Yesca...
Source: investingnews.com